Rituximab and Pegylated Interferon α-2b in Patients With Indolent B-cell Lymphoma

Clinical trial NCT04246359 · UNKNOWN

Trial details

NCT number: NCT04246359
Sponsor: Huiqiang Huang
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Lymphoma, B-Cell

Start date: 2020-01-15
Primary completion: 2022-06-16
Enrollment: 52

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.